People with heart failure could soon benefit from using Procoralan after it was recommended for use by the National Institute for Clinical Excellence (NICE).
NICE said the drug, which contains ivabradine, has been shown to have beneficial effect in reducing mortality and improving the quality of life for patients.
Around 900,000 people in the UK are affected by heart failure, and data on Procoralan suggests it could cut death rates and the need for a patient to be taken to hospital with the condition.
NICE stated the drug could be considered as a treatment option if patients are still symptomatic after receiving optimised initial therapies, or when patients do not tolerate beta-blockers.
Professor Carole Longson, NICE director, said the prevalence of heart failure is expected to rise in the future as a greater number of people live longer, so it is therefore necessary to make use of better treatments for the condition.
She added the committee concluded that ivabradine could be considered a “cost-effective” use of NHS resources for treating chronic heart failure.
Procoralan costs about £10 a week and is already prescribed for patients in the UK with angina.